Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Karyopharm Therapeutics

Karyopharm Therapeutics reported $61.56M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Abbott ABT:US USD 14.53B 959M
Amgen AMGN:US USD 14.22B 1.47B
AstraZeneca AZN:LN USD 24.86B 1.43B
Avrobio Inc AVRO:US USD 14.3M 1.18M
Eli Lilly LLY:US USD 16.01B 1.13B
Enanta Pharmaceuticals ENTA:US USD 32.17M 9.16M
GlaxoSmithKline GSK:LN GBP 20.7B 2.11B
Incyte Corp INCY:US USD 1.01B 150.97M
J&J JNJ:US USD 60.37B 4.57B
Karyopharm Therapeutics KPTI:US USD 61.56M 10.45M
MacroGenics MGNX:US USD 45.61M 3M
Mirati Therapeutics MRTX:US USD 124.6M 34.85M
Nektar Therapeutics NKTR:US USD 59.88M 8.32M
Novartis NOVN:VX USD 30.55B 1.89B
Novartis NVS:US USD 30.55B 1.89B
Regeneron Pharmaceuticals REGN:US USD 3.1B 41.2M
Roche Holding ROG:VX 27.24B 170M
Sangamo BioSciences SGMO:US USD 57.84M 53.87M
Takeda 4502:JP JPY 2.48T 245.13B
TG Therapeutics TGTX:US USD 63.08M 9.88M
Ultragenyx Pharmaceutical RARE:US USD 218.18M 43.03M
Xencor XNCR:US USD 65.06M 1.21M